BARDA, part of the US department of Health and Human Services’ Administration for Strategic Preparedness and Response, is funding development by Israel’s Redhill of Opaganib (see here previously) for the treatment of the Ebola virus. https://nocamels.com/2024/10/us-government-funding-development-of-israeli-ebola-treatment/

Opaganib, a novel, twice-daily, oral medication developed by Israel’s RedHill Biopharma (see here previously) delivered a statistically significant increase in survival time in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study https://www.israel21c.org/drug-shows-promise-in-treating-often-fatal-ebola-disease/

Researchers at Israel’s Weizmann Institute have developed a small molecule that stops the coronavirus spike protein from attaching to the lungs’ ACE2 receptor. But it doesn’t damage ACE2’s normal function. (See also here for similarities with opaganib from Israel’s Redhill). … Continue reading →

A pre-clinical trial of opaganib from Israel’s Redhill (see here previously) shows that its strong antiviral and anti-inflammatory activities can inhibit any variant of the SARS-Cov-2 virus. Opaganib targets SK2 – a key enzyme used by the virus to replicate, … Continue reading →

Israel’s Redhill has completed its Phase 2 / 3 clinical trials of its opaganib treatment on 475 coronavirus patients in Israel, Europe and Brazil. In a few weeks it will declare the results. Opaganib works on the patient rather than … Continue reading →

Preliminary data from Phase 2 trials of opaganib from Israel’s Redhill (reported here previously) on 40 hospitalized Covid-19 patients showed positive results. Patients receiving opaganib had significantly reduced dependence on ventilators and faster time to discharge. https://www.prnewswire.com/il/news-releases/redhill-s-phase-2-3-covid-19-candidate-opaganib-reduces-ards-related-blood-clotting-in-preclinical-model-813822864.html

Six moderate to severe Israeli coronavirus patients have shown clinical improvement with the new opaganib  treatment from Israel’s Redhill (see here previously). All required less supplemental oxygenation, had higher lymphocyte counts and less lung inflammation. https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15261

Israeli biotech Redhill has announced that another of its pipeline medicines RHB-107 (upamostat) is to be tested by the US National Institute of Allergy and Infectious Diseases (NIAID) against SARS-CoV2, the virus that causes COVID-19. (Redhill’s Opaganib is already saving … Continue reading →

Italy has approved Opaganib from Israel’s Redhill Biopharma to treat some 160 severe COVID-19 patients with severe respiratory problems at three hospitals in northern Italy. Phase2 tests on 131 US patients were positive and two critically ill Israeli patients are … Continue reading →